- Report
- July 2025
- 375 Pages
Global
From €5140EUR$5,850USD£4,434GBP
- Report
- July 2025
- 390 Pages
Global
From €5140EUR$5,850USD£4,434GBP
- Report
- July 2025
- 138 Pages
Global
From €5140EUR$5,850USD£4,434GBP
- Report
- July 2025
- 381 Pages
Global
From €5140EUR$5,850USD£4,434GBP
- Report
- July 2025
- 272 Pages
Global
From €5140EUR$5,850USD£4,434GBP
- Report
- July 2025
- 294 Pages
Global
From €5140EUR$5,850USD£4,434GBP
- Report
- July 2025
- 464 Pages
Global
From €5140EUR$5,850USD£4,434GBP
- Report
- July 2025
- 377 Pages
Global
From €5140EUR$5,850USD£4,434GBP
- Report
- July 2025
- 383 Pages
Global
From €5140EUR$5,850USD£4,434GBP
- Report
- July 2025
- 464 Pages
Global
From €5140EUR$5,850USD£4,434GBP
- Report
- July 2025
- 217 Pages
Global
From €5140EUR$5,850USD£4,434GBP
- Report
- July 2025
- 228 Pages
Global
From €5140EUR$5,850USD£4,434GBP
- Report
- July 2025
- 594 Pages
Global
From €5140EUR$5,850USD£4,434GBP
- Report
- July 2025
- 291 Pages
Global
From €5140EUR$5,850USD£4,434GBP
- Report
- July 2025
- 468 Pages
Global
From €5140EUR$5,850USD£4,434GBP
- Report
- July 2025
- 178 Pages
Global
From €5140EUR$5,850USD£4,434GBP
- Report
- July 2025
- 475 Pages
Global
From €5140EUR$5,850USD£4,434GBP
- Report
- July 2025
- 282 Pages
Global
From €5140EUR$5,850USD£4,434GBP
- Report
- July 2025
- 459 Pages
Global
From €5140EUR$5,850USD£4,434GBP
- Report
- July 2025
- 207 Pages
Global
From €5140EUR$5,850USD£4,434GBP

The Targeted Therapies market within the context of Genomics is focused on the development of treatments that target specific genetic mutations or pathways. These therapies are designed to be more effective and have fewer side effects than traditional treatments. Genomics has enabled the development of personalized treatments that are tailored to the individual patient's genetic makeup. This has allowed for the development of drugs that target specific mutations or pathways, leading to more effective treatments.
The Targeted Therapies market is a rapidly growing field, with many companies investing in research and development. Companies such as Gilead Sciences, Novartis, and AstraZeneca are leading the way in the development of targeted therapies. Other companies such as Merck, Pfizer, and Roche are also investing in the development of targeted therapies. Show Less Read more